TextSearch

Clinicians should consider age, sex, and vaccine type when accounting for vaccination risks, according to the authors of an observational study.

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The overall risk of developing myocarditis after COVID-19 vaccination is low, according to a new report from British Columbia, Canada.Because of certain risk factors, however, researchers recommended preferential use of the Pfizer–BioNTech vaccine over the Moderna vaccine for patients aged 18-29 years. Dr Naveed Janjua "Overall, myocarditis after SARS-CoV-2 vaccination was low but higher in younger males, especially after the second Moderna mRNA vaccine. After the third dose, rates of myocarditis were lower," study author Naveed Janjua, MBBS, DrPH, an epidemiologist and executive director of data and analytic services at the British Columbia Centre for Disease Control in Vancouver, told Medscape Medical News."Although observed rates of myocarditis were higher than expected, the benefits of the vaccine in reducing the severity of COVID-19, hospital admission, and deaths far outweigh the risk of developing myocarditis," he said.The study was published online November 21 in Canadian Medical Association Journal.British Columbia CohortThe investigators analyzed administrative data from the British Columbia COVID-19 Cohort from December 2020 to March 2022. They focused on the mRNA-1273 vaccine manufactured by Moderna and the BNT162b2 vaccine manufactured by Pfizer–BioNTech and accounted for differences in age, sex, dose number, and vaccine type. Credit: Lead image: Dreamstime Image 1: BCCDC Image 2: Vanderbilt University Medical Center Medscape Medical News © 2022 WebMD, LLC Send news tips to [email protected]. Cite this: Myocarditis Appears Rare After COVID-19 Vaccination - Medscape - Nov 22, 2022.